On the BSE, 88,000 shares were traded in the counter so far, compared with average daily volumes of 1.06 lakh shares in the past one quarter. The stock had hit a high of Rs 770 and hit a low of Rs 750 so far during the day. The stock had hit a 52-week high of Rs 1,498.40 on 23 March 2017. The stock had hit a 52-week low of Rs 756.50 on 7 March 2018.
The large-cap company has equity capital of Rs 90.42 crore. Face value per share is Rs 2.
Lupin today announced the signing of an agreement with CSIR-National Chemical Laboratory (CSIR-NCL, Pune) and Department of Science and Technology, (DST, Delhi) for conducting research on a continuous purification process development of a biosimilar monoclonal antibody therapeutic.
Monoclonal antibodies represent the most important biopharmaceutical product class, serving the highdemand treatment area of immuno-oncology diseases. With an increasing demand for biosimilar therapeutics and an ever-increasing pressure for manufacturing cost reduction with quality maintenance, the biopharmaceutical industry is showing keen interest in the development of continuous manufacturing processes.
Through this research collaboration, CSIR-NCL and Lupin would collaboratively work towards the development of a novel continuous purification process for manufacturing a biosimilar monoclonal antibody therapeutic (mAb).
Lupin's consolidated net profit plunged 64.98% to Rs 221.73 crore on 12.73% decline in total income to Rs 4004.63 crore in Q3 December 2017 over Q3 December 2016.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)